Residual adrenal function in Autoimmune Addison’s Disease—effect of dual therapy with rituximab and depot tetracosactide

In autoimmune Addison's disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion. Patients on long-term steroid replacement have increased morbidity, reduced life expectancy, and poorer quality of life.This article is freely available via Open Access. Click on the Publisher URL to access the full-text